129 related articles for article (PubMed ID: 15670502)
1. [CpG oligodeoxyribonucleotide with HBsAg for vaccination in HBsAg-transgenic mice].
Sun YH; Zhu CM; Xie Y
Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):61-2. PubMed ID: 15670502
[No Abstract] [Full Text] [Related]
2. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.
Malanchère-Brès E; Payette PJ; Mancini M; Tiollais P; Davis HL; Michel ML
J Virol; 2001 Jul; 75(14):6482-91. PubMed ID: 11413315
[TBL] [Abstract][Full Text] [Related]
3. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
Li X; Yang X; Li L; Liu H; Liu J
Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
5. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
Ma R; Du JL; Huang J; Wu CY
Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
[TBL] [Abstract][Full Text] [Related]
6. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
[TBL] [Abstract][Full Text] [Related]
7. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice.
Qin W; Jiang J; Chen Q; Yang N; Wang Y; Wei X; Ou R
Cell Mol Immunol; 2004 Apr; 1(2):148-52. PubMed ID: 16212903
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
Song ES; Park SA; Kim SH; Cho YJ; Ahn BY; Ahn BC; Lee NG
FEMS Immunol Med Microbiol; 2007 Dec; 51(3):496-504. PubMed ID: 17877731
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of immune responses to hepatitis B vaccine in immunodepressed mice by CpG oligodeoxynucleotide.
Qin WB; Jiang JW; Yang N; Chen QE; Wang YF; Wei XC; Ou RQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):647-50. PubMed ID: 15555425
[TBL] [Abstract][Full Text] [Related]
10. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
11. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
Li Y; Kandimalla ER; Yu D; Agrawal S
Int Immunopharmacol; 2005 Jun; 5(6):981-91. PubMed ID: 15829414
[TBL] [Abstract][Full Text] [Related]
12. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.
Davis HL; Suparto II; Weeratna RR; Jumintarto ; Iskandriati DD; Chamzah SS; Ma'ruf AA; Nente CC; Pawitri DD; Krieg AM; Heriyanto ; Smits W; Sajuthi DD
Vaccine; 2000 Mar; 18(18):1920-4. PubMed ID: 10699341
[TBL] [Abstract][Full Text] [Related]
13. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA.
Shen E; Li L; Li L; Feng L; Lu L; Yao Z; Lin H; Wu C
Cell Mol Immunol; 2007 Apr; 4(2):113-20. PubMed ID: 17484805
[TBL] [Abstract][Full Text] [Related]
14. The 3' CCACCA sequence of tRNAAla(UGC) is the motif that is important in inducing Th1-like immune response, and this motif can be recognized by Toll-like receptor 3.
Wang Z; Xiang L; Shao J; Yuan Z
Clin Vaccine Immunol; 2006 Jul; 13(7):733-9. PubMed ID: 16829609
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.
Sablan BP; Kim DJ; Barzaga NG; Chow WC; Cho M; Ahn SH; Hwang SG; Lee JH; Namini H; Heyward WL
Vaccine; 2012 Mar; 30(16):2689-96. PubMed ID: 22342916
[TBL] [Abstract][Full Text] [Related]
16. The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination.
Du X; Zheng G; Jin H; Kang Y; Wang J; Xiao C; Zhang S; Zhao L; Chen A; Wang B
J Gene Med; 2007 Feb; 9(2):136-46. PubMed ID: 17310492
[TBL] [Abstract][Full Text] [Related]
17. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.
Siegrist CA; Pihlgren M; Tougne C; Efler SM; Morris ML; AlAdhami MJ; Cameron DW; Cooper CL; Heathcote J; Davis HL; Lambert PH
Vaccine; 2004 Dec; 23(5):615-22. PubMed ID: 15542181
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles.
Borges O; Tavares J; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Eur J Pharm Sci; 2007 Dec; 32(4-5):278-90. PubMed ID: 17884394
[TBL] [Abstract][Full Text] [Related]
19. Generation of anti-idiotypic antibodies that mimic HBsAg and vaccination against hepatitis B virus.
Yildirim T; Başalp A; Yücel F; Manav AI; Sezen IY
Hybrid Hybridomics; 2004 Jun; 23(3):192-7. PubMed ID: 15312311
[TBL] [Abstract][Full Text] [Related]
20. Nanodecoy system: a novel approach to design hepatitis B vaccine for immunopotentiation.
Goyal AK; Rawat A; Mahor S; Gupta PN; Khatri K; Vyas SP
Int J Pharm; 2006 Feb; 309(1-2):227-33. PubMed ID: 16406404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
